ZURICH–The European Medicines Agency Friday recommended Novartis AG’s (NVS) cancer drug Afinitor for approval in the European Union for the treatment of advanced breast cancer, supporting the Swiss company’s hopes that the drug may become a blockbuster as it wins approval for use in different types of cancer.
Novartis said the EMA’s Committee for Medicinal Products for Human Use is backing …
No comments:
Post a Comment